Statements (62)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Farxiga
|
| gptkbp:activities |
gptkb:drug
|
| gptkbp:affects |
cardiovascular benefits
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:brand |
gptkb:Farxiga
|
| gptkbp:can_be_used_with |
gptkb:metformin
|
| gptkbp:category |
gptkb:C
not recommended |
| gptkbp:clinical_trial |
Phase III
glycemic control as monotherapy adjunct to diet and exercise in combination with other antidiabetic agents |
| gptkbp:contraindication |
end-stage renal disease
severe renal impairment hypersensitivity to dapagliflozin |
| gptkbp:dosage_form |
gptkb:tablet
tablets 10 mg once daily 5 mg once daily |
| gptkbp:effective_date |
gptkb:2014
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
film-coated tablet
|
| gptkbp:government_type |
new drug application
|
| gptkbp:has_ability |
weight loss
|
| https://www.w3.org/2000/01/rdf-schema#label |
dapagliflozin
|
| gptkbp:indication |
heart failure
chronic kidney disease |
| gptkbp:ingredients |
gptkb:dapagliflozin_propanediol
C21 H25 Cl O6 S |
| gptkbp:interacts_with |
gptkb:Company
diuretics sulfonylureas |
| gptkbp:is_used_for |
type 2 diabetes
|
| gptkbp:lifespan |
12.9 hours
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:temple
|
| gptkbp:metabolism |
liver
|
| gptkbp:population |
adults
|
| gptkbp:research_focus |
weight loss
long-term safety glycemic control renal outcomes cardiovascular outcomes |
| gptkbp:safety_features |
renal function
risk of bladder cancer risk of bone fractures risk of ketoacidosis |
| gptkbp:scholarships |
stay hydrated
consult healthcare provider before use monitor blood sugar levels report any signs of infection |
| gptkbp:side_effect |
dehydration
hypoglycemia urinary tract infections kidney injury may lower blood pressure genital mycotic infections |
| gptkbp:storage |
room temperature
|